AIHW logo
METEOR logo
Our sites
AIHW GEN Aged Care Data Aboriginal and Torres Strait Islander
Health Performance Framework
Indigenous Mental Health and
Suicide Prevention Clearinghouse
Australian Mesothelioma Registry Housing data Regional Insights for Indigenous Communities
Contact FAQs
  • Find metadata
    • Find metadata
    • Getting started
    • Data set specifications
    • Indicator sets
    • Data quality statements
    • Data dictionary archives
  • Metadata management
    • Metadata management
    • Data standards
    • Registration authorities
    • Registration statuses
  • How to use METEOR
    • How to use METEOR
    • First steps
    • Using My Page
    • Downloading and printing
    • FAQs
    • About METEOR
  • Learn about metadata
    • Learn about metadata
    • Metadata explained
    • How to create metadata
    • Metadata development resources

Prostate cancer (clinical) NBPDS

Identifying and definitional attributes

Metadata item type:Help on this termData Set Specification
METEOR identifier:Help on this term481386
Registration status:Help on this term
  • Health, Standard 14/05/2015
DSS type:Help on this termData Set Specification (DSS)
Scope:Help on this term

The purpose of the Prostate cancer (clinical) National best practice data set (PCNBPDS) is to define data standards for the national collection of prostate cancer clinical data so that data collected is consistent and reliable. Collection of this data set is not mandated but it is recommended as best practice where clinical cancer data are collected. It will facilitate more consistent data collection while enabling individual treatment centres or health service areas to develop data extraction and collection processes and policies that are appropriate for their service settings.

The PCNBPDS is used in conjunction with the Cancer (clinical) National best practice data set (CCNBPDS). Mandatory reporting regulations have enabled population-based cancer registries in Australia to collect standard information on all incident cases of cancer apart from non-melanoma skin cancers, from which incidence, mortality and overall survival have been determined and trends monitored. The CCNBPDS provides a framework for the collection of more detailed and comprehensive clinical data such as stage of cancer at diagnosis, other prognostic characteristics, cancer treatment and patient outcomes.

The PCNBPDS will support prospective data collection from the time a person with cancer symptoms is referred or first presents to a hospital or specialist through the entire duration of their illness.

The definitions used in this data set are designed to capture the provision of cancer care on a day-to-day level. They relate to the cancer care pathway and the need to optimise care by correctly diagnosing, evaluating and managing patients with cancer. In addition, end-points and patterns of care can be monitored to understand both the appropriateness and effectiveness of cancer care.

The data elements specified provide a framework for:

  • promoting the delivery of evidence-based care to patients with cancer
  • facilitating the ongoing improvement in the quality and safety of cancer management in treatment settings
  • improving the epidemiological and public health understanding of cancer informing treatment guidelines; and
  • professional education guiding resource planning and the evaluation of cancer control activities.

They will facilitate the aggregation of data across different treatment centres.

The underlying long-term goal is to provide data support to improve outcomes for patients by increasing the quality and length of life. For example, a comparison of the actual management of patients with best practice guidelines may identify shortfalls in treatment and limitations in access to treatment modalities for some patients.

Collection and usage attributes

Guide for use:Help on this term

This data set is primarily directed at the clinical and clinical epidemiological use of cancer data. Treatment centres such as hospitals, radiotherapy centres and cancer specialist practices are the settings in which implementation of the Prostate cancer (clinical) NBPDS should be considered. The data set can also be used by a wider range of health and health-related establishments that create, use, or maintain records on health-care clients.

Comments:Help on this term

Glossary items

Glossary terms that are relevant to this data set are included here.

Androgen deprivation therapy

Brachytherapy

Clinical trial

Core biopsy

Erectile dysfunction

Extraprostatic extension

Faecal incontinence

Gleason score

Medical imaging

Prostate-specific antigen

Radiotherapy

Sexual Health Inventory for Men

Surgical procedure

Urinary incontinence

Urine voiding problems

 

Source and reference attributes

Submitting organisation:Help on this term

Cancer Australia

Relational attributes

Related metadata references:Help on this term
See also Cancer (clinical) NBPDS
  • Health, Standard 14/05/2015

Metadata items in this Data Set SpecificationHelp on this term

Show more detail
Seq No.Help on this termMetadata itemHelp on this termObligationHelp on this termMax occursHelp on this term
1Person—erectile dysfunction extent, SHIM score NN

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

Mandatory99
2Person—erectile dysfunction assessment date, DDMMYYYYMandatory99
3Person—faecal incontinence indicator, yes/no/unknown code N

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

Mandatory99
4Person—urinary incontinence indicator, yes/no/unknown code N

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

Mandatory99
5Person—urinary incontinence pad use indicator, yes/no/unknown code N

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

Mandatory99
6Person—urine voiding problem, symptom severity code N

DSS specific information:

Collect this item at the point of diagnosis of a man with prostate cancer (prior to the initiation of treatment).

Mandatory99
7Person—prostate-specific antigen level, nanograms per millilitre

DSS specific information:

It is recommended that this item should be recorded at:

  • diagnosis
  • pre-treatment
  • post treatment
  • all subsequent follow-ups
Mandatory99
8Person—prostate-specific antigen test date, DDMMYYYY

DSS specific information:

Collect in conjunction with Person—Prostate-Specific Antigen Test level, nanograms per millilitre.

Mandatory99
9Person—prostate cancer diagnostic imaging, code NNMandatory19
10Person—prostate cancer diagnostic imaging, text X[X(99)]

Conditional obligation:

Collect this item when Person—diagnostic imaging, prostate cancer diagnostic imaging code NN equals other.

Conditional9
11Person with cancer—diagnostic histology indicator, yes/no/unknown code NMandatory1
12Person with prostate cancer—tissue collection method, code N

Conditional obligation:

Collect this item if Person with cancer-diagnostic histology, yes/no/unknown code N equals yes.

Conditional9
13Person with cancer—biopsy core, number N[NN]

Conditional obligation:

Collect this item if Person with cancer—diagnostic histology indicator, yes/no/unknown code N equals yes.

Conditional9
14Person with cancer—positive biopsy core, number N[NN]

Conditional obligation:

Collect this item if Person with cancer-diagnostic histology, yes/no/unknown code N equals yes.

Conditional9
15Person with cancer—core biopsy length, total millimetres NN.NOptional19
16Person with cancer—core biopsy tumour extent, percentage N[NNN]Optional19
17Person with cancer—core biopsy tumour length, total millimetres NN.NOptional19
18Person with cancer—histopathological grade, Gleason score code N[N]Mandatory19
19Person with cancer—histopathological grade, primary Gleason grade code NMandatory19
20Person with cancer—histopathological grade, secondary Gleason grade code NMandatory19
21Person with cancer—histopathological grade, tertiary Gleason Grade code NMandatory19
22Person with cancer—lymphovascular invasion type, code N

DSS specific information:

Collect this item both after diagnostic testing/imaging is completed and after surgery.

Mandatory9
23Person with cancer—perineural invasion indicator, yes/no/not applicable/not stated/inadequately described code N

DSS specific information:

Collect this item both after diagnostic testing/imaging is completed and after surgery.

Mandatory9
24Person with cancer—extraprostatic extension focality, code N

Conditional obligation:

Collect this item if Person with cancer—extraprostatic extension, yes/no/unknown/not stated/inadequately described code N equals yes and has been collected as part of the surgical removal of cancer. Do not collect this item if this relates to diagnostic assessment.

Conditional9
25Person with cancer—extraprostatic extension indicator, present/indeterminate/not identified code NMandatory1
26Person with cancer—extraprostatic extension location, code N[N]

Conditional obligation:

Collect this item if Person with cancer—extraprostatic extension, yes/no/unknown/not stated/inadequately described code N equals yes based on surgical pathology.

Conditional9
27Person with cancer—distant metastatic site(s) at diagnosis, code N[N]

Conditional obligation:

Record when cancer has metastasised to other sites.

Mandatory9
28Person with cancer—distant metastatic site(s) at diagnosis, topography code (ICD-O-3) ANN.N

Conditional obligation:

Collect this item when Person with cancer—distant metastatic site(s) at diagnosis, code N[N] equals other.

Conditional19
29Person with cancer—clinical trial entry status, code NMandatory9
30Person with cancer—clinical trial identifier, text X[X(399)]

Conditional obligation:

Collect this item when Person with cancer—clinical trial entry status, code N equals 2.

Conditional9
31Person with cancer—date clinical trial entered, DDMMYYYY

Conditional obligation:

Collect this item when Person with cancer—clinical trial entry status, code N equals 2.

Conditional9
32Person with cancer—date clinical trial completed, DDMMYYYY

Conditional obligation:

Collect this item when Person with cancer—clinical trial entry status, code N equals 2.

Conditional9
33Person with cancer—clinical trial experimental agent or intervention, text X[X(399)]

Conditional obligation:

Collect this item when Person with cancer—clinical trial entry status, code N equals 2.

Conditional9
34Cancer treatment—surgical procedure for prostate cancer, code NMandatory9
35Person with cancer—pelvic lymph node dissection indicator, yes/no/not stated/inadequately described code NMandatory1
36Person with cancer—pelvic lymph node dissection laterality, code AMandatory19
37Person with cancer—tumour focality indicator, code N

DSS specific information:

Record this item in relation to surgical pathology only.

Mandatory9
38Cancer treatment—surgical margin status, positive/negative/unknown code NMandatory9
39Cancer treatment—external beam radiotherapy type, code N[N]

Conditional obligation:

Collect if the patient has undergone external beam radiotherapy.

Conditional9
40Cancer treatment—brachytherapy indicator, yes/no code NMandatory1
41Cancer treatment—brachytherapy dose rate, code N

Conditional obligation:

Collect if Cancer treatment—brachytherapy, yes/no code N equals yes.

Conditional9
42Cancer treatment—androgen deprivation therapy indicator, yes/no/not applicable code NMandatory1
43Cancer treatment—androgen deprivation therapy purpose, code N

Conditional obligation:

Collect this item when Cancer treatment—androgen deprivation therapy, yes/no/not applicable code N equals yes.

Conditional9
44Cancer treatment—specialist support services type, code N[N]Mandatory29
45Cancer treatment—specialist support services type, text X[X(99)]

Conditional obligation:

Collect this item when Cancer treatment—specialist support services type, code N[N] equals other.

Conditional29
46Cancer treatment—specialist support services date, DDMMYYYY

Conditional obligation:

Collect this item when Cancer treatment—specialist support services indicator, yes/no/unknown code N equals yes.

Conditional29
47Person with cancer—castrate resistance indicator, yes/no code NMandatory1
48Person with cancer—castrate resistance date, DDMMYYYY

Conditional obligation:

Collect this item when Person with cancer—castrate resistance, yes/no code N equals yes.

Conditional9
Help
Downloading

The download may take a while, please wait.

Do not refresh the screen until the download is complete.

<Title>

<body>
<footer>
  • View
  • Show more
  • Print view
  • Download
  • Word™
  • Pdf
  • Advanced Download
  • Review
  • Compare items
© Australian Institute of Health and Welfare
Version 1.0.0+20220531.2